<DOC>
	<DOCNO>NCT00998985</DOCNO>
	<brief_summary>This multiple dose study assess safety , tolerability , pharmacokinetics pharmacodynamics grazoprevir ( MK-5172 ) Genotype ( GT ) 1 GT3 Hepatitis C virus ( HCV ) - infected participant . The primary hypothesis administration grazoprevir 7 day sufficiently safe well tolerate HCV-infected male .</brief_summary>
	<brief_title>A Study Grazoprevir ( MK-5172 ) Hepatitis C-Infected Male Participants ( MK-5172-004 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Baseline health stable . Has clinical diagnosis chronic HCV infection . Has history stroke chronic seizure . Has history cancer . Has history human immunodeficiency virus ( HIV ) infection . Has major surgery , donate blood participate another investigational study within past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>